Lluís Puig Sanz-rekin lankidetzan egindako argitalpenak (3)

2023

  1. Apremilast treatment of plaque psoriasis (PsO) after systemic therapy in Spanish clinical practice: Data from the APPROPRIATE study

    JEADV Clinical Practice, Vol. 2, Núm. 3, pp. 488-501

  2. Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 10, pp. 2004-2015

2021

  1. Definition of minimal disease activity in psoriasis

    Journal of the European Academy of Dermatology and Venereology, Vol. 35, Núm. 2, pp. 422-430